Is TG Therapeutics (TGTX) overvalued or fairly valued?

MarketChacha shows TG Therapeutics's valuation in context — a trailing P/E of about 20.2, a forward P/E of about 18.8, a price-to-book of about 13.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is TG Therapeutics's revenue?

TG Therapeutics reported revenue of $616.3M for FY2025, with net profit of $447.2M, per official filings.

What is the share price of TG Therapeutics (TGTX)?

TG Therapeutics last traded at $55.85 (-1.5% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

TG Therapeutics

TGTX · NYSE · Healthcare · United States

Snapshot

TickerTGTX

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees399

HeadquartersMorrisville, United States

Websitewww.tgtherapeutics.com

Filings tracked15

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Who owns it

Insiders7.5%
Institutions74.1%
Public & other18.4%

547 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.14.41%
Vanguard Portfolio Management LLC5.20%
State Street Corporation5.09%
Vanguard Capital Management LLC4.02%
Geode Capital Management, LLC2.38%
Shaw D.E. & Co., Inc.2.22%
Soleus Capital Management, L.P.1.91%
Price (T.Rowe) Associates Inc1.81%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Over 3 years only -0.20× of reported profit became operating cash — the classic sign that headline earnings may be running ahead of the cash actually generated. Often explained by working capital funding growth; worth a closer look.

Cash conversion-0.20×

Net margin trend5.4% → 7.1%

Margin has expanded by about 1.7 points — the business is getting more profitable.

Return on equity69.0%

Latest ROE of 69.0% — capital is generating a healthy return.

Growth qualityrev 62% · PAT 494%

Profit has grown much faster than revenue while recent results carried sizeable one-off items — some of the profit growth may not repeat.

One-off items1 of last 3 yrs

Recent reported profit includes sizeable one-off / non-operating items — the underlying operating trend may differ from the headline.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $267.9M · EPS 0.45

Est. earnings growth +217.9%

Next fiscal year

Rev $1.3B · EPS 2.96

Est. earnings growth +212.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$616.3M

ROE

69.0%

Revenue CAGR (2y)

+62.4%

Profit CAGR (2y)

+494.0%

EPS (FY2025)

2.77

Net profit (FY2025)

$447.2M

Ask MarketChacha about TGTX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$616.3M	$447.2M*	2.77	—	69.0%
FY2024	$329.0M	$23.4M	0.15	7.1%	10.5%
FY2023	$233.7M	$12.7M	0.09	5.4%	7.9%

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$240.3M	$7.8M	0.05	3.2%
2026Q1	$204.9M	$19.8M	0.12	9.7%
2025Q3	$161.7M	$390.9M*	2.43	—
2025Q2	$141.1M	$28.2M	0.17	20.0%
2025Q1	$120.9M	$5.1M	0.03	4.2%
2024Q3	$83.9M	$3.9M	0.02	4.6%
2024Q2	$73.5M	$6.9M	0.04	9.4%
2024Q1	$63.5M	$-10.7M	-0.07	-16.9%
2023Q3	$165.8M	$113.9M*	0.73	—
2023Q2	$16.1M	$-47.6M	-0.34	-296.2%
2023Q1	$7.8M	$-39.2M	-0.28	-502.8%

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q — FORM 10-Q
SEC8/5/2026
8-K — Results of operations, Exhibits
SEC8/3/2026material
8-K — Shareholder vote results
SEC6/12/2026material
8-K — Other events, Exhibits
SEC6/3/2026material
8-K — Other events, Exhibits
SEC5/27/2026material
8-K — Results of operations, Exhibits
SEC5/6/2026material
10-Q — FORM 10-Q
SEC5/6/2026
8-K — Material agreement, Material financial obligation, Exhibits
SEC3/20/2026material
10-K — FORM 10-K
SEC2/27/2026
8-K — Results of operations, Exhibits
SEC2/26/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/13/2026material

2025

10-Q — FORM 10-Q
SEC11/5/2025
8-K — Results of operations, Exhibits
SEC11/3/2025material
10-Q — FORM 10-Q
SEC8/8/2025
8-K — Results of operations, Exhibits
SEC8/4/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.